Shockwave therapy, or Extracorporeal shockwave therapy (ESWT) to give it its full nomenclature, sends mechanical shock waves into the affected area to stimulate the natural healing process by triggering the body’s own repair mechanisms.
The therapy is being spearheaded at Willows by Kinley Smith (pictured right), an RCVS and European specialist in small animal surgery. He said: "Shockwave therapy is a whole new line of treatment and has proved a spectacular success.
"It’s an excellent technique for dealing with certain orthopaedic conditions and there’s no invasive surgery, no wound to heal and no risk of infection so it really is a win-win-win procedure.
"It is particularly effective in the treatment of ligament and tendon injuries.
"There can be immediate pain relief for the dog; after two weeks we start to see lasting benefits and in four weeks we normally see a clear improvement.
"The added bonuses are we can normally reduce any medication; the dog can enjoy more exercise plus it is not as costly as undergoing an operation.
"Surgery is still essential in some of the more acute, problematic cases but shockwave therapy has been a terrific development in helping us provide an alternative treatment in a lot of soft tissue, muscle and bone conditions."
For more information, visit www.willows.uk.net.
Elanco Companion Animal Health has launched Recuvyra 50mg/ml transdermal solution for dogs, the first transdermal fentanyl solution to be licensed for the control of postoperative pain associated with major orthopaedic and soft tissue surgery.
Recuvyra is a schedule two controlled drug which contains fentanyl, a pure μ-agonist synthetic opioid with a potency 100 times that of morphine1. Applied to the area between the shoulder blades by a needleless two-pronged adapter two to four hours prior to surgery, Elanco says Recuvyra provides at least four days of opioid analgesia, which is mainly due to the activation of the μ-opioid receptors inhibiting the perception of pain and the transmission of pain signals in the spinal cord and dorsal horn2.
Elanco says Recuvyra's unique formulation provides long-lasting analgesia by establishing a depot of fentanyl within the stratum corneum. The fentanyl in this depot undergoes passive diffusion down a concentration gradient, and is steadily released into the general circulation over a number of days.
Ed Whittle MA VetMB MRCVS, technical consultant at Elanco said: "Fentanyl is widely used in human health and its powerful analgesic properties are well known amongst veterinary surgeons1, 3, 4. Recuvyra is a ground-breaking veterinary product that will provide long-acting post-operative pain control in dogs while reducing the need for repeated, invasive administration of analgesics in the practice and improved client compliance and the potential for mutimodal analgesia once a dog returns home."
To ensure proper use of Recuvyra, Elanco has produced a mandatory online training programme for veterinary surgeons to complete before ordering the product. The brief online training module, which can be viewed at www.recuvyratraining.eu, features information on the presentation, correct preparation and administration of the product, and the safe handling of patients that have been treated with Recuvyra. Once veterinary surgeons are trained, it is their responsibility to train their staff on the in-practice use of Recuvyra and Elanco has produced a training presentation to help educate veterinary professionals about the product.
To support the launch of Recuvyra, Elanco has produced a dosing calculator, cage cards and client information sheet. For further information on Recuvyra, please contact your Elanco Companion Animal Health key account manager or email elancocah.uk@elanco.com.
References
Intervet/Schering-Plough Animal Health is to launch CICADA-Live, the second phase of its national initiative to monitor the awareness and regional prevalence of important diseases in cats, dogs and rabbits.
First launched in 2007 as a quarterly survey, the ground-breaking CICADA-Live project has now been developed to offer up-to-the minute data on infectious companion animal disease reports that can be updated and accessed by vet practices around the clock. The new scheme is now able to provide a real-time overview of companion animal infectious diseases being diagnosed in UK veterinary practices.
CICADA-Live is focusing on more than a dozen key infectious diseases of dogs, cats and rabbits. They include canine parvovirus, infectious canine hepatitis, canine distemper, leptospirosis, kennel cough, angiostrongylosis. For cats, CICADA-Live will monitor feline panleucopaenia, cat flu, feline leukaemia virus infections. For rabbits the focus will be on myxomatosis, rabbit viral haemorrhagic disease, E.cuniculi, and fly strike.
The service is officially launched on 1st June to coincide with Intervet/Schering-Plough Animal Health's National Vaccination Month 2009, and is open to all first-opinion UK companion animal veterinary practices.
The system's developer, John Helps, Veterinary Manager at Intervet/Schering-Plough Animal Health said: "Whereas our first edition of CICADA was useful in providing benchmarks so that seasonal and long term trends could be identified and communicated to both vets and pet owners, the further potential of a live on-line database is enormous in raising awareness of current pet disease risks to the public."
According to the company, there has been a lack of knowledge regarding the local and national incidence of small animal infectious diseases in the UK, and those sporadic reports that do occur are typically anecdotal and can prove hard to substantiate. It is feared that the lack of co-ordinated good quality information has potentially lead to pet owners being lulled into a false sense of security by a low awareness of disease risks.
John added: "Lack of data on the incidence and prevalence of even the most common infectious diseases has been an important issue faced by small animal practices reducing their ability to highlight these risks. A staggering lack of owner awareness to infectious disease threats in turn contributes to complacency among pet owners.
"Evidence suggests that some infectious diseases, such as parvovirus, may be on the increase in some areas and there continues to be a concern regarding the number of animals that remain unvaccinated.
"Not only will Cicada-Live provide the means for improving a gap in our collective knowledge but it will also prove invaluable in the promotion of good preventative healthcare.
"We have long believed that better epidemiological surveillance would an important tool in understanding trends in small animal infectious disease and with CICADA-Live, for the first time we have a tool to give us a better appreciation of what first opinion practices are currently seeing."
The CICADA-Live website, http://www.cicadasurvey.co.uk/, is simple to access and update. Registrations are limited to one per practice branch. A straightforward one-page survey format minimises the time investment, with no strict requirement to review written case records.
Once signed in, participating practices will be asked to complete the survey once every 6 months in order to grant continued access to maps and tables showing recent reports. In addition practices can set up e-mail alerts to give notification should disease reports be received in their area.
For further information about CICADA-Live from Intervet please contact Intervet /Schering-Plough Animal Health's Veterinary Support Group on 01908 685685. Or contact John.
The tool is available to all practices, free of charge.
The downloadable and printable guide chart, which has been created by a number of specialists, will help veterinary surgeons, nurses and receptionists to identify urgent, potentially urgent, non-urgent and delayable cases to help limited veterinary resources be used to best efficiency without compromise to animal health or welfare.
The chart, which can be printed and put on a practice wall or referred to as a webpage via a mobile phone or tablet, has a number of supporting resources produced by the same specialists.
Sue Paterson, BSAVA President, said: “During these exceptional and worrying times veterinary surgeons need as much practical help and support as possible.
"We are hugely grateful for the indefatigable support of an enthusiastic group of volunteers who have rapidly produced this triage tool, which we are now able to share. It should enable patient queries to be processed, reliably and efficiently, allowing for emergency patients to be seen as a matter of urgency, within the current government and RCVS guidelines."
The triage tool is free to download and share: https://www.bsava.com/TriageTool
BSAVA is working on a number of other initiatives to support veterinary professionals during the current crisis, including new guidance on obtaining consent remotely for veterinary treatment. for more information, visit: https://www.bsava.com/adviceforCOVID19
The aim of the competition is to highlight top tips for pet owners and the benefits of building a den to help calm and reassure dogs during the fireworks festivities.
Practices that want to take part in the in the competition need to post pictures of their dens and waiting rooms on the Ceva Animal Health Facebook page in October. The winning practice will receive a £200 voucher and there are 10 runner up prizes of luxury chocolate hampers.
Abigail King, behaviour product manager at Ceva Animal Health, said: "Our hugely popular fireworks display competition encourages veterinary practices to create eye-catching and imaginative displays that help educate pet owners on what can be done at home to help calm and reassure pets with firework fears."
Ceva has a range of marketing materials for veterinary practices to use in the competition, including waiting room materials.
For further information, contact your Ceva territory manager.
Amanda Melvin, Senior Product Manager, said: "We’re very excited about this approval as it will allow us to build on the success of our Bravecto chewable tablets for dogs and provide veterinarians and cat owners with another tool in the fight against ticks and fleas. Being able to offer a full 12 week protection means convenience for cat owners and improved compliance rates for veterinarians, so everyone benefits."
Bravecto is applied topically using the new "Twist’n’Use" pipette design which means the cap doesn’t need to be removed.
Full product details are described in the summary of product characteristics (SPC).
For more information, contact your MSD Animal Health representative.
The Sutton Bonington Campus, home of the University of Nottingham's School of Veterinary Medicine and Science, has raised £610 for Sport Relief with its annual Science Cake Competition.
There were thirty entries to the competition, in categories which included Animals & Agriculture, Food & Nutrition, Infection, 'Nerdy' Science, Plants, Crops & Environment, and Veterinary Medicine.
A special category this year was 'Cakes for Animals', which Emily Blight, an undergraduate vet student, organised for a panel of dogs to judge on tastiness.
The winner of the public vote was 'What came first, the chicken or the cake?' (pictured right), whilst the overall winner was Alex Burgess with ‘Dave’s Allotment’.
One of the judges, Dr Mike Jones said: "Choosing the winner was extremely hard. Every cake had its own specific merits be it the execution of the design, through to the novelty of ingredients and ideas or how they fitted into the categories." He added that he "was almost put off jelly beans for life - they will be forever associated with sheep back sides."
The cakes are all on display here.
Mr Wood was convicted of three offences which involved the download of 38 videos and 13 indecent images of children, at Portsmouth Magistrates’ Court in December 2017.
In January 2018, he was sentenced to a three-year Community Sentence for each offence, to run concurrently, and was made subject to a five-year Sexual Harm Prevention Order.
He was also fined £1,000 and ordered to pay costs of £340 and a victim surcharge of £85.
Mr Wood was also placed on the barring list by the Disclosure and Barring Service and required to register with the police pursuant to the Sexual Offences Act 2003 for a period of five years.
Mr Wood appeared before the Disciplinary Committee, admitted his conviction and accepted that it rendered him unfit to practise veterinary surgery.
In determining the sanction, the Committee says it took into account a number of mitigating factors: his conviction involved no actual harm or risk of harm to an animal; there was no financial gain; he had engaged in open and frank admissions at an early stage; he was experiencing mental ill-health at the time of the offence; he had taken subsequent steps to avoid a repetition of such behaviour; there had been a significant lapse of time since the incident; and he showed insight into the harm caused by his offence.
The Committee also considered that the purpose of a sanction is not to punish, but to protect the welfare of animals, as well as maintain public confidence in the profession and declare and uphold proper standards of conduct. On consideration of the appropriate sanction, the Committee decided that postponement of judgement was not appropriate, and that taking no action was not an option.
The Committee then considered whether a reprimand or warning was appropriate, but they considered that would not match the gravity of the offence – a period of suspension would also mean Mr Wood would automatically return to the Register after the period of time without the College being able to review his fitness to practise, rendering it an inappropriate sanction. The Committee therefore determined that the removal of Mr Wood from the RCVS Register was the only way to protect the wider public interest and maintain confidence in the profession.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee has not taken this decision lightly, and, lest it be misinterpreted, it has not taken it in order to satisfy any notional public demand for blame and punishment.
"It has taken the decision because in its perception, the reputation of the profession had to be at the forefront of its thinking and ultimately it was more important than the interests of the Respondent.
"The decision is not simply based on the fact that these offences were of a sexual nature but because they were repeated frequently over a significant period of time, and at the time, the Respondent knew on his own admission that what he was doing was wrong.
"Accordingly, the Committee had decided that removal from the Register is appropriate and proportionate in this case. The Committee will direct the Registrar to remove the Respondent’s name from the Register forthwith."
Mr Wood has 28 days to appeal the Committee’s decision after which, if no appeal is received, the Committee’s judgment takes effect.
The RCVS is encouraging veterinary surgeons, veterinary nurses and other members of the practice team to respond to a government consultation on changing the law to introduce English language testing for veterinary surgeons who have qualified from elsewhere in the European Union.
Under the proposals outlined in the consultation by the Department for Environment, Food and Rural Affairs (Defra), the test would apply before an individual joined the Register and only where the RCVS had ‘serious and concrete doubts’ about their English language abilities. The plan to consult on this issue had been welcomed by RCVS Council at its June 2015 meeting.
Every year, around half of all new veterinary surgeon registrants are from outside the UK, the majority from other EU or European Economic Area (EEA) countries. These individuals fall within the scope of the Mutual Recognition of Professional Qualifications (MRPQ) Directive, which applies to all EU nationals wishing to practise in a regulated profession in another member state.
Last year, a revised version of the MRPQ Directive came into force, which made a number of changes, including clarifying and reinforcing the role of competent authorities such as the RCVS. One of these changes is that language testing is expressly permitted, but only where serious concerns have been identified.
Gordon Hockey, RCVS Registrar, said: “Under the current legislation the College is not able to bar someone from joining the Register, and therefore practising, on the basis of language ability, even where we may have serious concerns.
“I would encourage all veterinary surgeons, veterinary nurses and other members of the practice team to engage with this consultation and consider whether the College should have the right to impose a language test where it has serious doubts, more in line with medical doctors, and the form such testing would take.”
Under the proposals, applicants would be asked a series of questions concerning their language qualifications, experience and general ability to use the English language before registering. Depending on how they answer the questions they may then have to pass a language test before registering, or delay their application while they improve their language skills.
The consultation results will inform the College’s work with Defra to determine whether to proceed with implementation and, if so, to develop the most appropriate system of language testing. The College would implement language testing for veterinary nurses in parallel with any changes for veterinary surgeons.
Those who wish to take part in the consultation can do so at https://consult.defra.gov.uk/animal-health-and-welfare/vet_language_controls. The deadline for responses is Wednesday 30 September 2015.
A survey published today by the veterinary recruitment agency recruit4vets has found 45.8% of salaried veterinary surgeons earning less than £35K per annum.
251 veterinary surgeons in full-time permanent employment took part in the survey, the largest number (37%) working in the south east and London.
The survey found that the typical starting salary was £31K per annum, rising to 41K for a more experienced vet in small animal practice, and £44K for more experienced large animal practitioners. The survey also found that senior vets with over 20 years experience earn up to £69K.
The survey also looked at locum charge-out rates, which varied from £220-£230 per day (17%) to over £250 (15%), with the greatest number (29%) charging between £240-£250.
62% of locums said their hourly pay rate had not changed in the last 12 months, compared to 45% of permanent staff who said their salary was unchanged over the period. This despite 65% of vets saying that the demands on them within the practice had increased in the last 12 months.
Recruit4vets has produced a couple of video presentations about the results, locum pay covered here and permanent pay covered here.
Visit VetSurgeon.org Jobs for the largest selection of classified jobs for veterinary surgeons.
The company says that as soon as it discovered the unauthorised external access to its systems, it took them offline and started working to contain the threat.
Specialist third party consultants have been engaged to investigate the nature and extent of the incident and CVS has also informed the relevant authorities, including the Information Commissioner’s Office, because of the risk of malicious access to personal information.
The company says the majority of IT services for its practices and business functions have now been restored, but due to the increased levels of security and monitoring, some systems are not working as efficiently as before.
CVS also says that as a result of the incident, it is bringing forward plans to migrate its practice management system and related IT infrastructure to the cloud.
Analysis of the incident is ongoing and CVS says it will provide a further update in due course.
The survey, which this year had a record 1605 respondents, covers everything from basic earnings, bonuses and dividends to benefits such as accommodation, car allowance and pensions.
The survey found that the median salary package for all vets in 2021 was £48,325; £3000 more than in 2020.
For all nurses the median package was £24,227 in 2021 and for head nurses the figure rose to £31,013.
The median daily rate for a locum vet was £350 in 2021, a rise of over 16% since 2020.
The hourly locum rate increased by 36% to £41 per hour.
Similarly, locum nurse daily rates have risen by over 30% since 2020 to £144 and their hourly rate increased by 14% to £20.
New grad vets' salary packages actually dropped by £800 in 2021, to £32,700.
However, the 2021 new grad hourly rate increased to £15.66 from £15.04 in 2020.
SPVS says this could indicate that newly qualified vets are earning less because they are working, on average, three hours less a week.
This may suggest that they are prioritising their work life balance, with time off being more important than an overall salary.
SPVS also highlights a growing gender gap in salary.
81% of the respondents were female, and the median full time salary difference between men and women was 21%, compared to 15% in 2020.
SPVS hypothesises that this could be because there are more male vets in more senior positions, rather than because of gender per se.
The question, therefore, is why there are more male vets than females in senior positions.
The survey showed very similar numbers of males and females doing both clinical and non-clinical post graduate training. But more than twice as many men than women go on to take up positions of leadership or seniority, or in referrals.
More research is needed to understand why females are doing the extra training, but apparently not using it to further their career.
As in 2020 SPVS has also looked at satisfaction with remuneration, hours worked, conditions, support and prospects and is using this data to create a separate report which will be available soon.
For more information, visit: https://spvs.org.uk/spvs-survey/
In 2020, BSAVA Congress will have been held at the ICC Birmingham for thirty years. However, recent years have seen ever greater competition from the London Vet Show, so the plan to revitalise the event further north at an award-winning new venue with such good transport links seems to make a lot of sense.
Manchester Central's size also means that unlike in Birmingham, the commercial exhibition, lectures and demonstrations will all take place under one roof, maximising the use of delegates' time.
Angharad Belcher, Head of BSAVA Congress said: "We’ve had a first-class experience in Birmingham, and we could not have asked for more from the venue. We know that 2019 and 2020 will continue to be popular, however, it’s time to move BSAVA Congress forward and revitalise the offering to our delegates and exhibitors by bringing everything into one building. The move to Manchester enables us to invest even more in speakers and delegate experiences, to make BSAVA’s education programme truly unsurpassable."
BSAVA President Philip Lhermette said: "It’s very much a new city for a new Congress and celebrations will be in order. Manchester lends itself perfectly to a timely transformation for Congress. We will be completely re-branding the event, modernising the CPD programme and making the best possible use of every minute of every delegate’s time over the full four days. We have been working closely with the city and venue in practical terms to offer a whole suite of options to delegates and exhibitors, from irresistible new socials and extensive accommodation choices, to easy transport routes."
Shaun Hinds, CEO of Manchester Central said: "After getting to know the association and their vision, it was clear that they wanted to transform the experience of their delegates. The ambition of the association matches that of the city and Manchester has the perfect blend of venue and vibrancy to develop the BSAVA Congress of the future. We’re delighted to be welcoming them in 2021 and we’ll work hard with the organisers to create a unique and remarkable experience for their delegates, exhibitors, partners and all visitors."
NDSR’s European Specialist in neurology and neurosurgery Niklas Bergknut is performing the surgery.
He said: "This type of surgery for dogs is not performed in many clinics across the country.
"The pituitary gland is, of course, a very small gland which is very close to the brain, so it requires considerable expertise to perform the operation, followed by a lot of after-care to help the animal recover properly after surgery.
"The pituitary gland produces hormones which are essential for life, so it is then vital to constantly monitor the dog, its blood, hormones and fluid levels both during surgery and for a longer period after surgery.
"Although surgery may be challenging, the aftercare can be even more challenging and requires very skilled internal medicine specialists to manage the patients after surgery.
"Our medics and nurses carry out various blood tests and manage the fluid balance every hour after surgery and all the way through to the dog going home.
"Every department in the hospital has to work closely together to ensure the best possible treatment and the best possible outcome."
Niklas, who learned the technique from Bjorn Meij, Professor of Surgery at the University of Utrecht, described how the operation is performed. He said: "We go in through the mouth, up through the soft palate and into the underside of the cranium. Then you drill a little hole to access the tumour that way.
"It is obviously essential to make sure you are in exactly the right place or the outcome could be disastrous.
"It is also important to operate as early as possible before the tumour gets too big.
"Trying to remove a big tumour is more difficult and holds greater risks because of the damage that can be done to the surrounding brain in attempting to remove the tumour."
Niklas says that if surgery is successful, the results are impressive, with most dogs making a full recovery and not suffering any recurrence of the tumours, a better outcome than treating the dogs with traditional methods such as radiotherapy.
He added: "Removing the tumour like this is the only way of permanently treating tumours of this type. Radiotherapy is very good too but there is a much larger likelihood of the tumour growing back."
For more information, visit www.ndsr.co.uk.
DogStem has been shown to be effective, reducing pain and lameness and improving mobility and quality of life for three months to over twelve months following a single injection1,2.
In a prospective, randomised, double-blinded, placebo-controlled trial of DogStem, results showed that2:
TVM highlights how DogStem simplifies the process and reduces the cost of using stem cell therapy in practice because unlike previous therapies, it does not require require a surgical harvesting procedure to be carried out under general anaesthetic.
Helen Harrison, DogStem Technical Vet and Product Manager said: "Osteoarthritis is one of the most common diseases seen in veterinary practices and is challenging to manage.
"Conventional medical treatments typically address the symptoms rather than the underlying pathological processes.
"At the same time, local treatment options that slow progression of osteoarthritis have been limited and surgical interventions aren’t always possible or may be unrewarding.
"We’re delighted to be able to offer vets DogStem®, a stem cell product with a strong evidence base across numerous mobility and quality of life parameters.’
DogStem can be ordered from NVS, or direct from: www.dogstem.co.uk
Your tip could be clinical in nature (perhaps specific to a particular discipline, like cardiology or exotics), or to do with practice management, or dealing with clients, or HR, or, well, anything really.
To enter the competition, login to VetSurgeon.org and submit your tip in the forum, here.
Just before you press the button to post your tip, you might like to tick the box marked: "EMAIL ME REPLIES TO THIS POST" which appears immediately above the post button. That way, you'll get an email when someone else posts a tip.
Above each post in the forum, there is now a 'Thank You' link, which allows members to express their thanks for sharing something. The five tips that generate the largest number of 'thank yous' by the end of November will win the Amazon vouchers.
VetSurgeon.org is all about facilitating the sharing of knowledge, ideas and experience. So any tip entered into the competition will also be disseminated, together with the contributor's name, on other social media channels, such as Facebook, Twitter, Linkedin and if you include a photo, on Instagram.
VetSurgeon.org Arlo Guthrie said: "The competition is really designed to show off the new 'thank you' feature on VetSurgeon, which allows members to show their appreciation when someone shares something useful with their peers. In due course, we'll be running similar competitions for the most thanked photos and videos uploaded to our galleries. Watch this space."
Fitzpatrick Referrals has announced the launch of a new cancer and soft tissue surgery referral service headed by Professor Nick Bacon (pictured right) and Dr Laurent Findji.
Professor Bacon and Dr Findji are American and European Board-Certified Surgeons respectively, with extensive experience in cancer care and soft tissue surgery innovation.
Professor Bacon joins the service directly from his post as Head of Oncology at the University of Florida, College of Veterinary Medicine. He will also take up the position of part-time Chair of Oncology at the new University of Surrey School of Veterinary Medicine.
Dr Findji joins the team from his prior role as director of the VRCC in Essex, bringing his expertise in cancer and soft tissue surgery advancements.
Professor Noel Fitzpatrick, founder of Fitzpatrick Referrals, said: "With these two eminent and globally recognised Specialists leading the new service, the UK will now be able to provide an innovative approach and comprehensive diagnosis, treatment, management and prognosis for all cancer and soft-tissue patients. The service will also be able to use the additional expertise available through the University of Surrey and both Specialists will be available for referring vets to discuss cases and to offer advice on the innovative treatment options available."
Professor Stuart Carmichael, the new service's director, said: "We would only introduce a service like this when we know it can provide the best options, the most comprehensive care and the highest level of expertise available. This is a referral service which will change the way that cancer patients are dealt with in the UK."
Noel added: "It's a testament to the reputation of Fitzpatrick Referrals and the University of Surrey, our partner in education, that we have been able to attract talents as great as Nick and Laurent. This is an exciting time not only for the hospital, but also for first-opinion practices throughout the UK who can avail of this world-class opportunity to offer a potentially life-saving service to their clients for their patients."
The service will operate initially from a self-contained clinic at the existing Fitzpatrick Referrals Orthopaedic + Neurology Hospital in Surrey and will be accepting patients from 1st October.
The Animal Health Trust and the Kennel Club have announced that a new, non-invasive DNA test for the genetic mutation causing macular corneal dystrophy (MCD) in Labradors will be available from the Animal Health Trust DNA Testing Service from Monday 26 January 2015.
Macular corneal dystrophy (MCD) is a hereditary eye disease which, although painless, causes severe visual impairment in affected dogs.
The mutation for MCD is recessive; meaning only dogs that inherit two copies of the mutation will be affected. Dogs identified by the test as Clear have no copies of the mutation whereas Carriers have one copy of the mutation. Clears and Carriers cannot develop MCD, although Carriers will pass the mutation on to about half of their puppies if they reproduce. Dogs identified as Genetically Affected have two copies of the mutation and will develop MCD around middle-age. The DNA test can be used to screen dogs at any age and provides a means of eliminating the causal mutation from the Labrador Retriever gene pool.
Dogs affected with MCD will develop cloudy eyes, due to an abnormal accumulation of carbohydrates (known as glycosaminoglycans) in their corneas. The only treatment for the disease in people is to surgically perform a corneal transplant; however this has not yet been performed successfully in the dog for the treatment of MCD.
Dr Cathryn Mellersh, Head of Canine Genetics at the Animal Health Trust, said: "We're really pleased to be able to provide this new test in 2015. Screening Labradors for the mutation responsible for this condition will help to identify those dogs at risk of developing MCD, and/or passing it on to their puppies. Dogs don't typically develop MCD until middle age - so without a DNA test there is a chance that affected dogs are unknowingly bred from. Now, affected and carriers dogs can easily be identified through one simple test giving breeders peace of mind.
"By developing this test and encouraging screening within the Labrador population we hope that this horrible disease can now be eliminated from the breed. This is the aim behind all of our work in canine genetics and we're thrilled to have been able to make such good progress in developing this test after MCD was first reported in Labradors by one of own veterinary ophthalmologists in 2013. Since then we've worked closely with the ophthalmology team here at the Animal Health Trust and Labrador owners and breeders from various European countries and have managed to identify the mutation and launch this test within two years, which is great news for Labrador owners."
Caroline Kisko, Kennel Club Secretary, said: "The Labrador is the most popular breed in the UK, so there is certainly a high demand for puppies, and it is crucial that those being bred are as healthy as possible.
"This test will further assist breeders of Labradors in breeding healthy, happy examples of the breed and we are delighted to be able to offer another tool to improve and maintain the breed's health.
"The work carried out at the Kennel Club Genetics Centre at the Animal Health Trust really does make a massive difference to the lives of dogs and we are thrilled that Labrador breeders will now be able to make use of another health test to protect the health of the breed they love."
For more information, visit www.ahtdnatesting.co.uk. The test costs £48 inc VAT, with a 10% discount when at least 20 samples are submitted within a month. Interested parties should contact dnatesting@aht.org.uk with a start date to request a discount code.
Clare graduated from the University of Glasgow in 1991 and, following an internship at the University of Pennsylvania and general practice in Cambridgeshire, she completed a BSAVA/Petsavers Residency and was Staff Clinician in Neurology at the Royal Veterinary College.
Aged 26, she became the youngest ever Diplomate of the European College of Veterinary Neurology and three year later became a RCVS Specialist.
For 16 years, she operated a neurology and neurosurgery referral service at the Stone Lion Veterinary Hospital in Wimbledon and was awarded a PhD from Utrecht University in 2007.
Clare joined Fitzpatrick Referrals and the University of Surrey in 2013, was made a Fellow of the Royal College of Veterinary Surgeons in 2016 and awarded a Professorship of Veterinary Neurology in 2018.
Clare was made a Fellow of the Royal College of Veterinary Surgeons in 2016 in recognition of her meritorious contribution to the profession, including 25 years’ research into ‘Chiari-like malformation and syringomyelia’ in dogs.
Clare said: “I will be building and strengthening the neurology service at Wear to make it not just the leading centre in the North East, but in Europe.
“I love collaborating with others to find answers to the clinical problems we face and so, as well as potential partnership with my colleagues in the other disciplines at Wear, I hope to initiate or contribute to other multi-centre studies through the Linnaeus group.
“I am passionate about teaching and learning through collaboration, and I hope to bring multi-disciplinary rounds to the practice including neuro-radiology-neuropathology and neurology- behaviour.”
55 veterinary surgeons took part in the survey, which also found that only 37% of clinicians use FNA and cytology when investigating a suspected lipoma.
According to the survey, the biggest barriers to further investigations of lumps and bumps were cost (50%), short consult time (23%) and confidence in results (20%).
HT Vista, which earlier this year launched a cancer screening device for dogs which uses heat diffusion technology and AI to differentiate between benign skin masses and other tumours, is urging more practising vets to use an accurate screening process for early detection of malignant masses.
Dr. Gillian Dank, Board Certified Oncologist and Chief Veterinary Officer at HTVet, said: “There is no way to know that a mass is a lipoma based on palpation alone.
"The fact that a mass is subcutaneous, soft and circumscribed is not exclusive to lipoma and it could be a number of things including a mast cell tumour or sarcoma.
"On average a veterinary practice sees over 500 dermal and subcutaneous masses each year.
"We know anecdotally, and surveys like this confirm, that not every mass is aspirated – and that is why there is need for the HT Vista screening device.
"Every mass that comes in should be properly examined.”
“It’s interesting to see that the more experienced a clinician is, the less confident they are in diagnosing from palpation and this shows us that with experience we understand that our hands are not enough.”
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The survey showed that vets are conscious of the cost to clients, and also feel pressured due to time.
"We have developed the HT Vista to complement FNA and cytology, and hope clinicians find it a useful tool.
"Firstly, it is quick and affordable to scan, and for those masses that are benign it removes the need for unnecessary FNA’s.
"Secondly, vets are often wary of cost, however if a mass is scanned and the results indicate that further investigation is needed, there is more rationale to spend the extra money to get the cytology results.
"Finally, the device can offer complete confidence that malignancies are not being missed, and if a mass is malignant a prompt treatment plan can be initiated.”
https://www.vetreport.net/wp-content/uploads/2023/08/Lump-and-Bump-Survey-2023FINAL.pdf
https://ht-vista.uk
The product is marketed in a 10ml pack and has an expiry date of December 2017. The batch number is 6231-90D.
The 1ml syringe within the pack has 'Lbs' printed as the unit of measure instead of kg, which could lead to an incorrect dose being administered to dogs.
Any queries about returning this product should be addressed to:
Mr Ken Allen Qualified Person and Quality Advisor E-mail: ken.allen@norbrook.co.ukTelephone: + 02830 264435
During the four-day hearing, the Committee heard evidence in respect of three separate heads of charge brought against Mr Shah following a castration operation conducted on Shadow, a six-year old Newfoundland dog, which took place on 20 June 2014.
The three charges were as follows:
There was no complaint made as to the undertaking of the operation itself, and the Committee followed the advice from the Legal Assessor that each charge should be considered separately. When making its decision, the Committee did not take into account the fact that Shadow had died as it is impossible to say whether he would have survived had Mr Shah acted differently.
The Committee found each of the allegations against Mr Shah proved. In respect of the first charge the Committee heard from two expert witnesses, Professor Williams and Mr Plumley, who agreed that the decision to discharge Shadow at about 6pm on 20 June 2014, given his condition, was inappropriate.
The Committee considers that discharging Shadow at that time into the care of the owner given his state on discharge, was grossly negligent and a serious error of judgement. It therefore found Mr Shah to be guilty of the first charge.
The Committee then considered that, after being alerted to Shadow’s continued lack of progress by the telephone call from Gemma Ballantyne between 30 and 45 minutes after discharge, Mr Shah exacerbated the situation by the inadequacy of his response in dealing with the concerns raised which, in the Committee’s view, represented a continuation of his previous poor judgement.
The Committee considered that Mr Shah was under a duty of care to advise Gemma Ballantyne to seek urgent veterinary attention for Shadow and by his own admission he failed to do so, and he was therefore found guilty of the second charge.
During that telephone call Mr Shah also gave no further details about the out-of-hours care available to Gemma Ballantyne other than to inform her that there would be an additional cost.
He did not seek confirmation that any such information been supplied by his colleague, Emma Martin (who at the relevant time was a student nurse), however, and at no time did he see Gemma Ballantyne in possession of the discharge sheet. The Committee therefore found Mr Shah guilty of this final head of charge.
The Committee did accept that there was no element of dishonesty, nor was there an aim of financial gain in the case. The Committee also considered that Mr Shah was acting in good faith at all times. It also accepted that Mr Shah was entitled to assume that normal practice had been followed and that a previously compiled discharge sheet, containing the number of the out-of-hours provider, had been supplied to Miss Ballantyne.
Ian Green, chairing the Committee and speaking on its behalf, said: "Balancing all of the factors as the Committee must, it is clear that on this occasion Mr Shah’s conduct fell far short of that which is expected and it therefore finds he conducted himself disgracefully in a professional respect."
Mr Green added: "In imposing the sanction of a reprimand, the Committee urges Mr Shah in the strongest possible terms to ensure that his future conduct by way of training and support systems within his practice are such as to avoid any possibility of a future incident such as this occurring in order to ensure animal welfare and public confidence in the veterinary profession. The Committee notes that in her evidence, Emma Martin said that the working practices at the surgery have been changed and the Committee expects that all animals kept in the care of Mr Shah are fully monitored, examined and assessed in relation to their condition before being discharged."
Two analyses of the pet insurance market have been published this week, which together suggest that veterinary practices may be starting to price themselves out of the market.
Both reports are titled Pet Insurance 2014. In the first, published by Key Note Ltd, authors highlight a 35.4% increase in gross claims incurred on cat and dog insurance policies between 2009 and 2013, which is more than 5 times the increase in the volume of claims over the same period. It is the degree to which the value of claims has outstripped the volume which the report describes as 'undeniably the greatest factor affecting the UK market for pet insurance.
At the same time, there has been a relatively modest growth in the percentage of adults that own a cat or dog (around 1.5 percentage points). Consequently, premiums increased by 38.9% between 2009 and 2013 as insurers responded to the growing cost of claims.
Meanwhile, the other Pet Insurance 2014 report, this time from YouGov, has shown that the main factors limiting the uptake of pet insurance are poor value for money and the high cost of premiums. In 2012, 31% of owners without insurance said it was not good value for money, and that was the main reason for not taking out cover. By 2014, that figure had risen to 39% of the uninsured and 26% said they just cannot afford premiums.
According to the YouGov report, the words that uninsured pet owners most associate with pet insurance are 'expensive' (68%) and 'waste of money' (30%). Even 57% of those with insurance deem it expensive.
YouGov also highlighted that the number of uninsured pet owners who say they can afford to pay for veterinary treatment out of their own pockets (without setting money aside each month) has increased 4 percentage points from 15% in 2012 to 19% in 2014. YouGov hypothesises that this may be down to the improving economic situation in the UK, but it could equally be explained as just the way hard-pushed people self-justify their decision to discontinue insurance.
James McCoy, Research Director, YouGov Reports said: "Although social grade is important to being able to afford to take out pet insurance, our research suggests that those at different ends of the financial spectrum share the opinion that cover is not necessarily always a sound financial option.
"More affluent pet owners find insurance poor value because they can afford to pay for treatment up front; for less affluent pet owners, while pet insurance is perceived as offering good value for money, the cost of premiums is prohibitive, leading some to save money instead."
The poster grades faeces from one (kickable) to six (most certainly not kickable).
James Kyffin, Veterinary Director at Protexin Veterinary said: "We believe that Poop Points offers pet owners a fun and engaging way to monitor their pet’s faeces."
That, surely, must win James the "Oxymoronic Veterinary Quote of the Year Award 2019".
More seriously, he went on to say: "It is important to raise awareness of alterations in animal’s faecal scores and ensure that this is communicated to their veterinary surgeon in an effective way."
Practices in the UK and Ireland can order their free poster on Protexin's website: https://www.protexinvet.com/pooppoints, or by emailing info@protexin.com.
Protexin will also be promoting digestive health advice on its website and social channels (@Protexin Veterinary on Facebook and Instagram), which practices can share and use.
Boehringer Ingelheim Vetmedica Ltd has announced that Metacam is now available for use in pigs as an oral suspension.
Metacam, which contains the non-steroidal anti-inflammatory drug (NSAID) meloxicam, is indicated for the treatment of non-infectious locomotor disorders to reduce inflammation and signs of lameness. It is also licensed for the treatment of mastitis-metritis-agalactia (MMA) syndrome in sows, when used alongside appropriate antibiotic therapy. MMA is a multifactorial condition that can threaten the health of the sow and the lives of her piglets due to a marked decrease or complete cessation in milk production.
Boehringer says treatment with Metacam15 mg/ml oral suspension helps control inflammation and pain associated with the condition, thereby helping to restore productivity and wellbeing in the sow and her offspring.
Metacam 15mg/ml oral suspension for pigs supplements the existing injectable formulation and has been introduced to its increase flexibility and ease of use, and to reduce the potential stress than can be caused when injecting newly-farrowed sows. The palatable suspension can be given mixed with a small quantity of feed or can be administered directly into the mouth.